Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taltirelin for the treatment of obstructive sleep apnea
jRCTs031200308Completed
- Sponsor
- Apnimed, Inc.
- Start
- Apr 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of taltirelin in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Apnimed, Inc. Primary endpoint: Apnea–Hypopnea Index (AHI) by AASM criteria. Started Apr 2021; status: completed.
02
Drugs
taltirelin
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on jRCTs031200308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200308.